



**Figure S1.** Study flow chart.

LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; SBP: systolic blood pressure; eGFR: estimated glomerular filtration rate; Ace-i: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CrCl: Creatinine Clearance; K<sup>+</sup>: potassium.



**Figure S2.** Sacubitril Valsartan dosage at 6-month follow up.

**Table S1.** Multivariable regression stepwise analysis with changes in LAVi.

Changes in LAVi	Beta	Std. Err.	b	Std. Err.	P-value
<b>Changes in LVEDV</b>	-0.4292	0.1315	-0.4244	0.1300	<b>0.0024</b>
<b>Changes in PALS</b>	-0.3283	0.1290	-0.1259	0.0495	<b>0.0153</b>
<b>Baseline LVEDD</b>	-0.2361	0.1315	-0.0061	0.0034	0.0808

LVEDV: left ventricular end-diastolic volume; PALS: peak atrial longitudinal strain; LVEDD: left ventricular end-diastolic diameter In bold p value < 0.05.